What does this score mean?
The study is a controlled animal experiment published in Nature, including lifespan and numerous physiological measurements. Factors increasing the score are direct lifespan tracking and comparison with calorie restriction; the primary factor decreasing the score is that the data comes solely from female mice and there is an absence of lifespan outcomes in humans.
What did the study investigate?
It investigated whether GLP-1 receptor agonism initiated at an advanced age affects not only appetite and glucose control, but also aging biology and lifespan.
How was it conducted?
Twenty-month-old female C57BL/6 mice were administered semaglutide or control. In separate cohorts, treatment was continued for three months for physiological, cellular, and molecular measurements; in the lifespan cohort, it was maintained until death. In another experiment, semaglutide was directly compared for five months with a 24% calorie restriction providing an equivalent reduction in calories.
What was found?
Mice given semaglutide showed improvements in areas that decline with age, such as muscle and cognitive function, balance, coordination, endurance, and glucose tolerance. In the NIH’s assessment of the study, it was reported that the median lifespan of treated mice was approximately 100 days longer compared to the control group. Although caloric intake was similarly reduced, semaglutide and calorie restriction did not produce the same physiological profile; semaglutide demonstrated improvements above baseline in certain cognitive and glycemic measurements.
Limitations of the study
Data comes exclusively from female mice. Mouse biology does not fully represent human aging. The study did not demonstrate that semaglutide extends lifespan in healthy older humans. In addition, a patent application regarding the use of GLP-1 agonists in healthy aging was reported by the University of California.
What does it mean clinically?
The study strengthens the hypothesis that GLP-1 agonists may influence aging biology beyond their cardiometabolic effects. However, current clinical use must be based on obesity, diabetes, and related approved indications; this result does not justify the use of semaglutide as an “anti-aging drug” in healthy individuals.
What do we not know yet?
It remains unknown whether there is a similar effect on biological aging markers or lifespan in humans, whether the results are the same in males, the optimal dose-duration relationship, and the long-term benefit-risk balance.
Reference
Feng Y, Barthez M, Wang Y, et al. Late-life semaglutide treatment slows ageing and extends lifespan in female mice. Nature. 2026;657:469–476. DOI: 10.1038/s41586-026-10940-7. Publication date: September 2, 2026.
Related reading: Weight Management and Metabolic Health · Healthy Aging and Longevity
Written and medically reviewed by: Dr. Kerem Çağlayan · All Scientific Research
Detailed assessment
Why is it important?
The clinical benefits of GLP-1 agonists on cardiovascular, renal, and metabolic outcomes are known. This study tests the idea that the biology of aging may be affected as a common upstream mechanism. In particular, the direct comparison matched with calorie restriction makes an explanation solely through weight loss difficult.
Conclusion
The Nature study positions semaglutide as a potential calorie restriction mimetic and geroscience candidate. It should not be directly generalized to humans; however, it strongly justifies controlled human studies using biological aging endpoints.
Medical evaluation note: This content has been prepared to interpret scientific data; it is not a personal diagnosis or treatment recommendation.